Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771958 | 0.90 | MAP4K4 (0.35) | EGLN1SLC22A12 | |
| SCHEMBL3770604 | 0.88 | FFAR4 (0.33) | SLC22A12 | |
| SCHEMBL3152373 | 0.83 | EGLN1 (0.41) | EGLN1ARP2RX7KDM1A | |
| SCHEMBL3152381 | 0.81 | AR (0.38) | EGLN1ARP2RX7KDM1ASLC22A12 | |
| SCHEMBL3765795 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL3773171 | 0.78 | AR (0.38) | EGLN1ARP2RX7KDM1ASLC22A12 | |
| SCHEMBL3843144 | 0.78 | ABL1 (0.34) | SLC22A12 | |
| SCHEMBL3146047 | 0.76 | KDM1A (0.40) | EGLN1ARP2RX7KDM1AHCRTR1 | |
| Hydrochloric Acid SCHEMBL3774537 | 0.75 | KDM1A (0.39) | EGLN1ARP2RX7KDM1AHCRTR1 | |
| SCHEMBL3780227 | 0.74 | EGLN1 (0.38) | EGLN1KDM1ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | EGLN1 3487/4885AR 222/4885P2RX7 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.